Botox maker Allergan draws bid from Valeant (Update)

April 21, 2014 by Ken Sweet

Valeant Pharmaceuticals is teaming up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.

Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.

Allergan said it had no comment on the bid late Monday.

In a separate filing, Ackman's Pershing Square Capital Management said it owns a 9.7 percent stake in Allergan worth $4.1 billion. Ackman's stake would make an Allergan deal worth around $40 billion.

Valeant Pharmaceuticals International Inc. is one of Canada's largest pharmaceutical companies, with revenue of $5.8 billion last year. The company, headquartered in Laval, Quebec, has pursued an aggressive acquisition strategy. It's racked up more than 50 deals since 2008.

Last August, it completed an $8.7 billion acquisition of Bausch + Lomb, giving it a major stake in the market for contact lenses, eye drugs and eye surgical devices. Before that, the company's largest deals included a $1.65 billion tie-up with Biovail Corp. in 2010 and its $2.6 billion acquisition of dermatology products maker Medicis Pharma in December 2012.

Allergan, which is based in Irvine, Calif., has long been one of the star performers in the specialty pharmaceutical sector. "Specialty pharmaceutical" is an industry term that differentiates smaller drugmakers from much bigger companies that sell a wide array of drugs, such as Pfizer and Merck.

Allergan reported revenue of $6.3 billion last year, up 12 percent from 2012. The company's growth has been driven by expanding use of its blockbuster product, Botox, combined with a broad offering of eye care drugs, skin care formulas and breast implants.

Last year Botox sales rose 12 percent to nearly $2 billion. First introduced in 1989, the injectable drug is most famous for its ability to smooth wrinkle lines on aging foreheads. But over the years Allergan has racked up more than a half-dozen other approved uses for Botox, including treatment for neck spasms, eye muscle disorders and migraine headaches.

Allergan's stock jumped $29.50, or 21 percent, to $171.50 in after-hours trading.

U.S.-traded shares of Valeant rose $13.04, or more than 10 percent, to $139.05.

Explore further: FDA approves Botox for crow's feet

Related Stories

FDA approves Botox for crow's feet

September 11, 2013
If you have a high school reunion coming up, here's a medical development that you may want to keep an eye on.

Botox developer rues missing out on billions

February 13, 2012
Botox developer Alan Scott says he rues the day he handed over rights to the best-selling wrinkle-smoothing drug to a US company for just $4.5 million, saying he might have become a billionaire.

Valeant agrees to pay about $2.6B for Medicis

September 3, 2012
(AP)—Valeant Pharmaceuticals International Inc. has agreed to buy dermatology products maker Medicis Pharmaceutical Corp. for about $2.6 billion in cash in a deal to strengthen its position in skin treatments and care.

Valeant to buy Bausch + Lomb for $8.7B (Update)

May 27, 2013
Canadian drugmaker Valeant Pharmaceuticals said Monday that it will pay $8.7 billion to buy Bausch + Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of Valeant's smaller ophthalmology ...

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.